{"id":743013,"date":"2025-05-13T07:36:02","date_gmt":"2025-05-13T07:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=743013"},"modified":"2025-05-13T07:36:02","modified_gmt":"2025-05-13T07:36:02","slug":"stills-disease-treatment-market-poised-for-significant-growth-driven-by-therapies-targeting-novel-pathways-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/stills-disease-treatment-market-poised-for-significant-growth-driven-by-therapies-targeting-novel-pathways-delveinsight_743013.html","title":{"rendered":"Still’s Disease Treatment Market Poised for Significant Growth, Driven by Therapies Targeting Novel Pathways | DelveInsight"},"content":{"rendered":"
\n
\"Still's<\/a><\/div>\n
\n
Still’s Disease – Market Insight, Epidemiology And Market Forecast – 2032<\/div>\n<\/div>\n<\/div>\n
The Still’s disease treatment market is poised for significant growth driven by increasing disease awareness, improved diagnostic capabilities, and the emergence of novel therapeutic options. This growth is fueled by the introduction of innovative biological therapies by key players, including AB2 Bio, Roche, Novartis, Swedish Orphan Biovitrum, Jubilant Life Sciences, Hikma, Teva, and Horizon, among others, which are addressing significant unmet needs in this rare inflammatory condition.<\/div>\n

DelveInsight’s “Still’s Disease – Market Insight, Epidemiology And Market Forecast – 2032<\/a><\/strong>” report provides comprehensive insights into Still’s disease, including historical and forecasted epidemiology, current treatment approaches, and emerging therapies across the 7MM. The report presents a detailed understanding of the disease, historical and forecasted epidemiology, current treatment paradigms, emerging therapies, and market dynamics that will shape the Still’s disease landscape over the next decade.<\/p>\n

Still’s disease, encompassing both adult-onset Still’s disease (AOSD)<\/strong> and systemic juvenile idiopathic arthritis (sJIA)<\/strong>, is a rare autoinflammatory disorder characterized by persistent fever, typical salmon-colored rash, joint pain, and systemic inflammation. Recent research suggests these conditions may be part of a continuum of the same disease, prompting clinicians to seek unified approaches to diagnosis and management.<\/p>\n

According to DelveInsight’s latest market analysis, the Still’s disease market is projected to expand significantly by 2032. The US leads the market, followed by EU4 and the UK, due to better healthcare infrastructure and higher awareness.<\/p>\n

Download the Still’s disease Market Forecast Report to understand which factors are driving the Still’s disease therapeutic market @ Still’s disease Market Trends<\/a>.<\/strong><\/p>\n

Still’s disease epidemiological studies show that the total diagnosed prevalent cases of AOSD were approximately 2.5K in the US<\/strong> in 2023. Among the EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases of AOSD, followed by France and the UK. Furthermore, the condition exhibits a bimodal age distribution, typically affecting individuals between 15-25 years and 36-46 years of age, with some studies indicating a higher prevalence among females.<\/strong><\/p>\n

Discover evolving trends in the Still’s disease patient pool forecasts @ Still’s disease Epidemiology Analysis<\/a>.<\/strong><\/p>\n

The current treatment landscape for Still’s disease involves a stepwise approach, beginning with first-line therapies consisting of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs), followed by second-line options including methotrexate or cyclosporin A. However, recent clinical evidence demonstrates promising results for biological drugs, particularly interleukin inhibitors. A systematic review and meta-analysis revealed that IL-1 inhibitors (IL-1i) and IL-6 receptor inhibitors (IL-6Ri) show the highest level of efficacy in managing Still’s disease<\/strong>, with anakinra consistently ranked as the most effective intervention for achieving clinical responses. These biological therapies have demonstrated superior efficacy with favorable safety profiles, transforming the management approach for patients with limited treatment options.<\/p>\n

The Still’s disease pipeline contains several innovative therapies targeting novel pathways. Notable emerging treatments include Camoteskimab (CERC-007)<\/strong>, a high-affinity, fully human anti-IL-18 monoclonal antibody being developed by Apollo Therapeutics<\/strong>. The first Phase Ib clinical trial of CERC-007 for AOSD commenced in May 2021, with the primary objective of determining safety, tolerability, and preliminary efficacy. Another promising candidate is Tadekinig alfa (r-hIL-18BP), a recombinant human interleukin-18 binding protein developed by AB2 Bio that inhibits the proinflammatory cytokine IL-18. Swedish Orphan Biovitrum’s KINERET<\/strong>, an interleukin-1 receptor antagonist, is also under evaluation in a Phase III study for Still’s disease treatment.<\/p>\n

Recent clinical developments have underscored the therapeutic potential of targeting specific inflammatory pathways in Still’s disease. In February 2025, the FDA granted Priority Review to Sobi’s supplemental Biologics License Application for GAMIFANT<\/strong> for use in adults and children with hemophagocytic lymphohistiocytosis\/macrophage activation syndrome associated with Still’s disease, particularly in patients with inadequate response or intolerance to glucocorticoids, or with recurrent MAS. The target decision date (PDUFA) is June 27, 2025.<\/p>\n

Discover evolving trends in the Still’s disease treatment landscape @ Still’s disease Recent Developments<\/a>.<\/strong><\/p>\n

Despite these advances, significant challenges remain in the Still’s disease treatment landscape, including diagnostic delays due to the condition’s rarity and symptom overlap with other inflammatory disorders. The most severe complication, Macrophage Activation Syndrome (MAS), affects approximately 10-15% of patients<\/strong> and is associated with high mortality rates. This complication, along with treatment-related adverse effects and high therapy costs, represents substantial unmet needs that emerging therapies aim to address.<\/p>\n

Looking ahead, the Still’s disease market is expected to witness continued innovation focused on targeted therapies, combination approaches, and personalized treatment strategies. As research further elucidates the molecular mechanisms underlying the disease, next-generation biologics and small molecules targeting specific inflammatory pathways are likely to reshape treatment paradigms, potentially improving long-term outcomes and quality of life for patients with this challenging condition.<\/p>\n

Table of Contents<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary of Still’s Disease<\/p>\n

3. Competitive Intelligence Analysis for Still’s Disease<\/p>\n

4. Still’s Disease: Market Overview at a Glance<\/p>\n

5. Still’s Disease: Disease Background and Overview<\/p>\n

6. Still’s Disease Patient Journey<\/p>\n

7. Still’s Disease Epidemiology and Patient Population<\/p>\n

8. Still’s Disease Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Still’s Disease Unmet Needs<\/p>\n

10. Key Endpoints of Still’s Disease Treatment<\/p>\n

11. Still’s Disease Marketed Products<\/p>\n

12. Still’s Disease Emerging Therapies<\/p>\n

13. Still’s Disease: Seven Major Market Analysis<\/p>\n

14. Attribute analysis<\/p>\n

15. 7MM: Market Outlook<\/p>\n

16. Access and Reimbursement Overview of Still’s Disease<\/p>\n

17. KOL Views<\/p>\n

18. Still’s Disease Market Drivers<\/p>\n

19. Still’s Disease Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

23. About DelveInsight<\/p>\n

Related Reports:<\/strong><\/p>\n

Still’s Disease Pipeline Insight<\/a><\/p>\n

Still’s disease Pipeline Insight provides comprehensive insights about the Still’s disease pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Still’s disease companies, including Swedish Orphan Biovitrum, R-Pharm International, LLC, Syneos Health, Apollo Therapeutics Ltd, and AB2 Bio<\/strong>, among others.<\/p>\n

About DelveInsight<\/strong><\/p>\n

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Arpit Anand
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +14699457679
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Still’s Disease – Market Insight, Epidemiology And Market Forecast – 2032 The Still’s disease treatment market is poised for significant growth driven by increasing disease awareness, improved diagnostic capabilities, and the emergence of novel therapeutic options. This growth is fueled … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-743013","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/743013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=743013"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/743013\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=743013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=743013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=743013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}